Nivolumab,Ipilimumab
BMS
['nsclc', 'lioi', 'sclc', 'cm743']
 presenting the 4 yr update for cm743. meso diff to io/io in nsclc, while hr still strong, the plateauing of curves not so strong with meso. 1/3 non-epithelioid may explain this. better outcomes with io, but only 17% 4 yr survival #esmo22. 
Medical Oncologist, Translational Researcher, Peter Mac. Tweets are my own opinions. Musician (@mayhemtomi) https://t.co/f3ccD2Ml7v